Human CD42b/GPIb alpha Alexa Fluor® 350-conjugated Antibody Summary
Accession # P07359
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
Background: CD42b/GPIb alpha
Platelet glycoprotein Ib alpha chain (GPIb alpha ), also known as CD42b, is a 145 kDa type I transmembrane protein that is a member of the leucine-rich repeat (LRR) family of ligand binding proteins (1‑3). It is expressed by platelets as the ligand-binding subunit of the platelet GPIb-IX-V complex (4). Human CD42b contains a 16 amino acid (aa) signal sequence, a 489 aa extracellular domain (ECD), a 21-aa transmembrane domain, and a 100 aa cytoplasmic region. The ECD contains 8 LRRs, with # 2, 3, and 4 having been demonstrated to regulate shear-dependent adhesion to von Willebrand factor (vWF) (5, 6). The LRRs are followed by a thrombin-binding anionic region that includes three sulfated tyrosines, a sialomucin domain with N- and O-linked carbohydrates, and two cysteines near the membrane that allow dimerization (1‑6). Four human isoforms with 1 to 4 repeats of aa 398‑411 within the sialomucin domain of mature CD42b are known to exist but have unknown significance (7). The ECD of human CD42b shares 48‑51% aa identity with mouse, rat, bovine, and canine CD42b. The metalloproteinase TACE/ADAM17 constitutively and inducibly cleaves CD42b, between Gly480 and Val481. This releases a soluble form called glycocalicin that circulates at ~2 μg/mL (8, 9). CD42b binding to ligands such as thrombin, kininogen, and coagulation factors XI and XII helps to initiate platelet activation and coordinate the coagulation cascade (1, 10‑12). Binding of CD42b to vWF or thrombospondin in the plasma or matrix, vWF or P-selectin on endothelial cells, or the integrin alpha M beta 2 (MAC-1) on myeloid cells, controls response to vascular injury (1, 13). Bernard-Soulier syndrome and platelet-type von Willebrand disease are platelet function disorders that can be caused by mutations in CD42b (1, 14).
- Andrews, R.K. et al. (2007) Arterioscler. Thromb. Vasc. Biol. 27:1511.
- Lopez, J.A. et al. (1987) Proc. Natl. Acad. Sci. USA 84:5615.
- Wenger, R.H. et al. (1988) Biochem. Biophys. Res. Commun. 156:389.
- Luo, S-Z. et al. (2007) Blood 109:603.
- Uff, S. et al. (2002) J. Biol. Chem. 277:35657.
- Shen, Y. et al. (2006) J. Biol. Chem. 281:26419.
- Ishida, F. et al. (1995) Blood 86:1356.
- Gardiner, E.E. et al. (2007) J. Thromb. Haemost. 5:1530.
- Beer, J.H. et al. (1994) Blood 83:691.
- Adam, F. et al. (2003) Eur. J. Biochem. 270:2959.
- Baglia, F.A. et al. (2004) J. Biol. Chem. 279:49323.
- Bradford, H.N. et al. (2000) J. Biol. Chem. 275:22756.
- Wang, Y. et al. (2005) Circulation 112:2993.
- Othman, M. et al. (2005) Blood 105:4330.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD42b/GPIb alpha Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CD42b/GPIb alpha Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human CD42b/GPIb alpha Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image